Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic CD30.CAR-EBVSTs in CD30-positive lymphomas
NCT04952584Phase 1Withdrawn
- Sponsor
- Baylor College of Medicine
- Start
- Mar 2024
- Primary completion
- Jun 2025
- Modality
- CAR-T Cells, Native Immune Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD30.CAR-EBVST cells in Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), anaplastic large cell lymphoma (ALCL) and 3 more, sponsored by Baylor College of Medicine. Planned start Mar 2024; status: withdrawn.
02
Drugs
CD30.CAR-EBVST cells
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)anaplastic large cell lymphoma (ALCL)peripheral T-cell lymphoma (PTCL)Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)
Beyond the preview
Go deeper on NCT04952584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04952584.